About lexaria corp - LEXX
Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the IP licensing segment which generates revenue from customers by licensing its proprietary DehydraTECH technology. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
LEXX At a Glance
Lexaria Bioscience Corp.
740 McCurdy Road
Kelowna, British Columbia V1X 2P7
| Phone | 1-250-765-6424 | Revenue | 705.92K | |
| Industry | Pharmaceuticals: Major | Net Income | -11,901,841.00 | |
| Sector | Health Technology | 2025 Sales Growth | 52.047% | |
| Fiscal Year-end | 08 / 2026 | Employees | 7 | |
| View SEC Filings |
LEXX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 22.445 |
| Price to Book Ratio | 5.759 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.181 |
| Enterprise Value to Sales | 19.264 |
| Total Debt to Enterprise Value | 0.008 |
LEXX Efficiency
| Revenue/Employee | 100,846.143 |
| Income Per Employee | -1,700,263.00 |
| Receivables Turnover | 1.916 |
| Total Asset Turnover | 0.108 |
LEXX Liquidity
| Current Ratio | 2.322 |
| Quick Ratio | 2.322 |
| Cash Ratio | 1.317 |
LEXX Profitability
| Gross Margin | 83.203 |
| Operating Margin | -1,647.966 |
| Pretax Margin | -1,687.356 |
| Net Margin | -1,685.997 |
| Return on Assets | -182.503 |
| Return on Equity | -215.885 |
| Return on Total Capital | -384.052 |
| Return on Invested Capital | -212.262 |
LEXX Capital Structure
| Total Debt to Total Equity | 3.657 |
| Total Debt to Total Capital | 3.528 |
| Total Debt to Total Assets | 2.618 |
| Long-Term Debt to Equity | 2.639 |
| Long-Term Debt to Total Capital | 2.546 |